Relative ratio and level of amyloid-β 42 surrogate in cerebrospinal fluid of familial alzheimer disease patients with presenilin 1 mutations

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 166-170

  Tagami, Shinji ^a   Okochi, Masayasu ^a   Yanagida, Kanta ^a   Kodama, Takashi ^a   Arai, Tetsuaki ^b   Kuwano, Ryozo ^c   Ikeuchi, Takeshi ^c   Takeda, Masatoshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

Secretase; Secretase inhibitor; Alzheimer disease; Amyloid precursor like protein 1 derived A like peptide; Amyloid peptide; Amyloid like peptide; Presenilin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PRESENILIN 1; GAMMA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MARKER; FAMILIAL ALZHEIMER DISEASE; GENE MUTATION; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; TANDEM MASS SPECTROMETRY; ADULT; CASE REPORT; CONFERENCE PAPER; DISEASE COURSE; FAMILIAL DISEASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PRESENILIN-1; TANDEM MASS SPECTROMETRY;

EID: 84896701739     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000355258     Document Type: Article

References (15)

1. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-870.
2. Winkler E, Hobson S, Fukumori A, Dumpelfeld B, Luebbers T, Baumann K, Haass C, Hopf C, Steiner H: Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase. Biochemistry 2009; 48: 1183-1197.
3. Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M, Kopan R: A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA 2003; 100: 13075-13080.
4. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B: Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006; 96: 732-742.
5. Shimojo M, Sahara N, Murayama M, Ichinose H, Takashima A: Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. Neurosci Res 2007; 57: 446-453.
6. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B: Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 2010; 29: 3408-3420.
7. Deng Y, Tarassishin L, Kallhoff V, Peethumnongsin E, Wu L, Li YM, Zheng H: Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. J Neurosci 2006; 26: 3845-3854.
8. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, Mc-Gowan E: Abeta40 inhibits amyloid deposition in vivo. J Neurosci 2007; 27: 627-633.
9. Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA: Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 2005; 65: 323-325.
10. Kakuda N, Shoji M, Arai H, Furukawa K, Ikeuchi T, Akazawa K, Takami M, Hatsuta H, Murayama S, Hashimoto Y, Miyajima M, Arai H, Nagashima Y, Yamaguchi H, Kuwano R, Nagaike K, Ihara Y: Altered gamma-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol Med 2012; 4: 344-352.
11. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-648.
12. Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, Jiang J, Mori K, Tatsumi S, Arai T, Ikeuchi T, Kasuga K, Tokuda T, Kondo M, Ikeda M, Deguchi K, Kazui H, Tanaka T, Morihara T, Hashimoto R, Kudo T, Steiner H, Haass C, Tsuchiya K, Akiyama H, Kuwano R, Takeda M: The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol Med 2009; 1: 223-235.
13. Ikeda M, Yonemura K, Kakuda S, Tashiro Y, Fujita Y, Takai E, Hashimoto Y, Makioka K, Furuta N, Ishiguro K, Maruki R, Yoshida J, Miyaguchi O, Tsukie T, Kuwano R, Yamazaki T, Yamaguchi H, Amari M, Takatama M, Harigaya Y, Okamoto K: Cerebrospinal fluid levels of phosphorylated tau and Abeta1-38/Abeta1-40/Abeta1- 42 in Alzheimer's disease with PS1 mutations. Amyloid 2013; 20: 107-112.
14. Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, Nakayama T, Ihara Y, Takeda M: Gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave Abeta42 and Abeta43. Cell Rep 2013; 3: 42-51.
15. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM: {gamma}-Secretase substrate concentration modulates the Abeta42/Abeta40 ratio: implications for Alzheimer disease. J Biol Chem 2007; 282: 23639-23644.